ClinicalTrials.Veeva

Menu

Single Dose Versus 24 Hours Antibiotic Prophylaxis in Reduction Mammaplasty

D

Daniela Francescato Veiga

Status

Completed

Conditions

Anti-bacterial Agents
Mammaplasty
Prophylaxis
Plastic Surgery
Wound Infection

Treatments

Other: Sterile saline
Drug: Cephazolin

Study type

Interventional

Funder types

Other

Identifiers

Details and patient eligibility

About

Setting: Translacional Surgery Graduation Program - Universidade Federal de São Paulo and Hospital das Clínicas Samuel Libânio - Universidade do Vale do Sapucaí. Background: Breast reduction is one of the most performed plastic surgery procedures. Antibiotics are widely prescribed, on an empirical basis, to prevent surgical site infections. However, there is a lack of evidence to support its use. Objective: To compare the influence of the use of prophylatic antibiotics as a single dose or for 24 hours on surgical site infection rates following reduction mammaplasty. Methods: Randomized trial of non-inferiority, with two parallel groups, double blinded. A total of 146 breast hypertrophy patients, with reduction mammaplasty already scheduled, will be enrolled. Patients will be randomly allocated to group A, that will receive antibiotics only at the anesthesia induction (n=73), or to group B, that will receive antibiotics at the anesthesia induction and for 24 hours (n=73). None of the patients will receive antibiotics after hospital discharge. Patients will be followed-up weekly, for 30 days, regarding surgical site infection. The Centers for Disease Control and Prevention criteria will be applied. A statistical analysis of the data will be performed.

Enrollment

146 patients

Sex

Female

Ages

18 to 60 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • 18 and 60 years of age
  • body mass index (BMI) between 19 and 30 kg/m2
  • breast hypertrophy according to the criteria of Sacchini et al. and Franco and Rebello

Exclusion criteria

  • patients who had previously undergone another surgical procedure of the breast
  • patients who have been diagnosed with a breast pathology
  • smokers
  • patients who had a child or breastfed within the last year
  • patients with uncontrolled comorbidities, such as arterial hypertension or diabetes
  • use of immunosuppressants
  • patients who had any infection during the follow-up period, requiring the use of antibiotics
  • patients who present any adverse effects due to the antibiotics during the study
  • patients who miss follow-up assessments
  • patients who withdraw their consent at any time

Trial design

Primary purpose

Prevention

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Triple Blind

146 participants in 2 patient groups, including a placebo group

Cephazolin
Experimental group
Description:
Patients will receive antibiotics (1g cephazolin) intravenously at the anesthestic induction and every 6 hours for 24 hours
Treatment:
Drug: Cephazolin
Sterile saline
Placebo Comparator group
Description:
Patients will receive antibiotics (cephazolin) only at the anesthesia induction, and sterile saline intravenously every 6 hours for 24 hours
Treatment:
Other: Sterile saline

Trial contacts and locations

1

Loading...

Central trial contact

Joel Veiga-Filho, MD, PhD; Daniela F Veiga, MD, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems